MannKind (MNKD) News Today $6.85 +0.55 (+8.73%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wells Fargo Initiates Coverage of MannKind (MNKD) with Overweight RecommendationDecember 21 at 6:36 AM | msn.comMannKind initiated with an Overweight at Wells FargoDecember 20 at 8:18 PM | markets.businessinsider.comLeerink Partners Sticks to Its Buy Rating for MannKind (MNKD)December 20 at 8:18 PM | markets.businessinsider.comMannKind stock up 10% amid bullish Wells Fargo noteDecember 20 at 8:18 PM | msn.comMannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 yearsDecember 20 at 9:25 AM | finance.yahoo.comMannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wells Fargo & CompanyWells Fargo & Company started coverage on shares of MannKind in a research note on Friday. They set an "overweight" rating and a $9.00 target price on the stock.December 20 at 8:31 AM | marketbeat.comLeerink Partnrs Lowers Earnings Estimates for MannKindMannKind Co. (NASDAQ:MNKD - Free Report) - Research analysts at Leerink Partnrs cut their FY2026 EPS estimates for MannKind in a note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per shareDecember 20 at 7:57 AM | marketbeat.comRBC Capital Upgrades MannKind (MNKD)December 20 at 4:24 AM | msn.comRBC upgrades MannKind on royalty revenue, orphan lung pipelineDecember 19 at 11:06 PM | markets.businessinsider.comMannKind upgraded to Outperform from Sector Perform at RBC CapitalDecember 19 at 11:06 PM | msn.comMannKind (NASDAQ:MNKD) Trading Up 5.7% - Here's WhyMannKind (NASDAQ:MNKD) Trading 5.7% Higher - Time to Buy?December 19 at 3:15 PM | marketbeat.comMannKind (NASDAQ:MNKD) Upgraded to Outperform at Royal Bank of CanadaRoyal Bank of Canada upgraded MannKind from a "sector perform" rating to an "outperform" rating and raised their price target for the stock from $7.00 to $10.00 in a research report on Thursday.December 19 at 8:03 AM | marketbeat.comMannKind Corporation Announces Exchange of Convertible Notes for Stock and CashDecember 18 at 7:22 PM | finance.yahoo.comLeerink Partners Keeps Their Buy Rating on MannKind (MNKD)December 18 at 7:22 PM | markets.businessinsider.comMannKind announces exchange of convertible notes for stock, cashDecember 18 at 7:22 PM | markets.businessinsider.comMannKind (NASDAQ:MNKD) Shares Gap Up - Still a Buy?MannKind (NASDAQ:MNKD) Shares Gap Up - Here's What HappenedDecember 18 at 1:08 PM | marketbeat.comMannKind to reduce debt by 84%December 18 at 7:54 AM | seekingalpha.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by HighTower Advisors LLCHighTower Advisors LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 300.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,393 shares of the biopharmaceutical company's stock after buyDecember 18 at 3:34 AM | marketbeat.comMannKind (NASDAQ:MNKD) Stock Price Down 5.4% - Here's WhyMannKind (NASDAQ:MNKD) Stock Price Down 5.4% - Here's What HappenedDecember 17, 2024 | marketbeat.comMannKind Corporation: A Speculative Buy On IPF And Diabetes MarketsDecember 17, 2024 | seekingalpha.comWellington Management Group LLP Increases Stake in MannKind Co. (NASDAQ:MNKD)Wellington Management Group LLP boosted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 11.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 865,295 shares of the biopharmaceutical company's stock after buying aDecember 17, 2024 | marketbeat.comMannKind Shares Are falling Today: What's Going On?December 16, 2024 | benzinga.comMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)December 16, 2024 | markets.businessinsider.comMannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 StudyDecember 16, 2024 | markets.businessinsider.comMannKind Corp (MNKD) Announces Promising Phase 3 Results for Afrezza in Pediatric Diabetes TreatmentDecember 16, 2024 | gurufocus.comMannKind reports six-month results from Phase 3 INHALE-1 trialDecember 16, 2024 | tipranks.comMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)December 16, 2024 | globenewswire.comMannKind, Cipla: CDSCO in India approves Afrezza Inhalation Powder in IndiaDecember 11, 2024 | markets.businessinsider.comMannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement BuildsDecember 11, 2024 | msn.comMannKind Corp (MNKD) Gains Approval for Afrezza in IndiaDecember 11, 2024 | gurufocus.comCDSCO Approves Afrezza® (insulin human) Inhalation Powder in IndiaDecember 11, 2024 | globenewswire.comTwo Sigma Advisers LP Buys 1,000,600 Shares of MannKind Co. (NASDAQ:MNKD)Two Sigma Advisers LP increased its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 60.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,648,327 shares of the biopharmaceutical company's stock after aDecember 9, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Downgraded by StockNews.com to HoldStockNews.com cut MannKind from a "buy" rating to a "hold" rating in a report on Saturday.December 7, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 381,298 Shares of MannKind Co. (NASDAQ:MNKD)BNP Paribas Financial Markets lifted its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 421.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 471,802 shares of the biopharmaceutical company's stock after acquiring an additional 381,298December 6, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Average Recommendation of "Buy" from AnalystsMannKind Co. (NASDAQ:MNKD - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The averageDecember 6, 2024 | marketbeat.com1,947,813 Shares in MannKind Co. (NASDAQ:MNKD) Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. bought a new stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,947,813 shares of the biopharmaceutical company's sDecember 5, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC boosted its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 37.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,304,085 shares of the biopharmaceutical companyDecember 4, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Rating Upgraded by StockNews.comStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Friday.November 29, 2024 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 67,536 Shares of StockNovember 26, 2024 | insidertrades.comGSA Capital Partners LLP Trims Stock Holdings in MannKind Co. (NASDAQ:MNKD)GSA Capital Partners LLP lowered its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 96.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,342 shares of the biopharmaceutical company's stock after selling 45November 26, 2024 | marketbeat.comInsider Sell Alert: Steven Binder Sells 67,536 Shares of MannKind Corp (MNKD)November 25, 2024 | gurufocus.comMannKind director Steven Binder sells $465k in stockNovember 25, 2024 | investing.comOptimistic Buy Rating for MannKind’s MNKD-201 Program Bolstered by Inhaled Drug Development SuccessNovember 25, 2024 | markets.businessinsider.comPrincipal Financial Group Inc. Purchases 134,937 Shares of MannKind Co. (NASDAQ:MNKD)Principal Financial Group Inc. increased its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 401.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 168,518 shares of the biopharmaceutical company'sNovember 24, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 251,587 Shares of MannKind Co. (NASDAQ:MNKD)Connor Clark & Lunn Investment Management Ltd. raised its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 15.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,885,370 shares of the biopharmaceutical cNovember 22, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Director Steven B. Binder Sells 67,539 SharesNovember 20, 2024 | insidertrades.comLeerink healthcare analysts hold an analyst/industry conference callNovember 19, 2024 | markets.businessinsider.comMannKind’s Growth Momentum and Increased Confidence in Pipeline Elevate Buy RatingNovember 12, 2024 | markets.businessinsider.comMannKind Co. (NASDAQ:MNKD) Given Average Rating of "Buy" by BrokeragesShares of MannKind Co. (NASDAQ:MNKD - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the coNovember 11, 2024 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.520.61▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼314▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Madrigal Pharmaceuticals News Halozyme Therapeutics News Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News Geron News Celldex Therapeutics News Dynavax Technologies News BioCryst Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts